In vivo uptake and metabolism of α-[11C]methyl-L- tryptophan in human brain tumors

Csaba Juhász, Diane C. Chugani, Otto Muzik, Dafang Wu, Andrew E. Sloan, Geoffrey Barger, Craig Watson, Aashit K. Shah, Sandeep Sood, Eser L. Ergun, Tom J. Mangner, Pulak K. Chakraborty, William J. Kupsky, Harry T. Chugani

Research output: Contribution to journalArticle

62 Citations (Scopus)

Abstract

Abnormal metabolism of tryptophan has been implicated in modulation of tumor cell proliferation and immunoresistance. α-[11C]Methyl-L- tryptophan (AMT) is a PET tracer to measure cerebral tryptophan metabolism in vivo. In the present study, we have measured tumor tryptophan uptake in 40 patients with primary brain tumors using AMT PET and standard uptake values (SUV). Tryptophan metabolism was further quantified in 23 patients using blood input data. Estimates of the volume of distribution (VD′) and the metabolic rate constant (k′3) were calculated and related to magnetic resonance imaging (MRI) and histology findings. All grade II to IV gliomas and glioneuronal tumors showed increased AMT SUV, including all recurrent/residual tumors. Gadolinium enhancement on MRI was associated with high VD values, suggesting impaired blood-brain barrier, while k′3 values were not related to contrast enhancement. Low-grade astrocytic gliomas showed increased tryptophan metabolism, as measured by k′3. In contrast, oligodendrogliomas showed high VD′ values but lower k′3 as compared with normal cortex. In astrocytic tumors, low grade was associated with high k′3 and lower VD′, while high-grade tumors showed the reverse pattern. The findings show high AMT uptake in primary and residual/recurrent gliomas and glioneuronal tumors. Increased AMT uptake can be due to increased metabolism of tryptophan and/ or high volume of distribution, depending on tumor type and grade. High tryptophan metabolic rates in low-grade tumors may indicate activation of the kynurenine pathway, a mechanism regulating tumor cell growth. AMT PET might be a useful molecular imaging method to guide therapeutic approaches aimed at controlling tumor cell proliferation by acting on tryptophan metabolism.

Original languageEnglish (US)
Pages (from-to)345-357
Number of pages13
JournalJournal of Cerebral Blood Flow and Metabolism
Volume26
Issue number3
DOIs
StatePublished - Mar 2006
Externally publishedYes

Fingerprint

Brain Neoplasms
Tryptophan
Neoplasms
Glioma
Magnetic Resonance Imaging
Cell Proliferation
tryptophan methyl ester
Kynurenine
Oligodendroglioma
Molecular Imaging
Astrocytoma
Gadolinium
Residual Neoplasm
Blood-Brain Barrier
Histology
Growth

Keywords

  • Blood-brain barrier
  • Brain tumors
  • Glioma
  • Molecular brain imaging
  • Positron emission tomography
  • Tryptophan metabolism

ASJC Scopus subject areas

  • Endocrinology
  • Neuroscience(all)
  • Endocrinology, Diabetes and Metabolism

Cite this

Juhász, C., Chugani, D. C., Muzik, O., Wu, D., Sloan, A. E., Barger, G., ... Chugani, H. T. (2006). In vivo uptake and metabolism of α-[11C]methyl-L- tryptophan in human brain tumors. Journal of Cerebral Blood Flow and Metabolism, 26(3), 345-357. https://doi.org/10.1038/sj.jcbfm.9600199

In vivo uptake and metabolism of α-[11C]methyl-L- tryptophan in human brain tumors. / Juhász, Csaba; Chugani, Diane C.; Muzik, Otto; Wu, Dafang; Sloan, Andrew E.; Barger, Geoffrey; Watson, Craig; Shah, Aashit K.; Sood, Sandeep; Ergun, Eser L.; Mangner, Tom J.; Chakraborty, Pulak K.; Kupsky, William J.; Chugani, Harry T.

In: Journal of Cerebral Blood Flow and Metabolism, Vol. 26, No. 3, 03.2006, p. 345-357.

Research output: Contribution to journalArticle

Juhász, C, Chugani, DC, Muzik, O, Wu, D, Sloan, AE, Barger, G, Watson, C, Shah, AK, Sood, S, Ergun, EL, Mangner, TJ, Chakraborty, PK, Kupsky, WJ & Chugani, HT 2006, 'In vivo uptake and metabolism of α-[11C]methyl-L- tryptophan in human brain tumors', Journal of Cerebral Blood Flow and Metabolism, vol. 26, no. 3, pp. 345-357. https://doi.org/10.1038/sj.jcbfm.9600199
Juhász, Csaba ; Chugani, Diane C. ; Muzik, Otto ; Wu, Dafang ; Sloan, Andrew E. ; Barger, Geoffrey ; Watson, Craig ; Shah, Aashit K. ; Sood, Sandeep ; Ergun, Eser L. ; Mangner, Tom J. ; Chakraborty, Pulak K. ; Kupsky, William J. ; Chugani, Harry T. / In vivo uptake and metabolism of α-[11C]methyl-L- tryptophan in human brain tumors. In: Journal of Cerebral Blood Flow and Metabolism. 2006 ; Vol. 26, No. 3. pp. 345-357.
@article{c6910dcbc286478b8eeb56ded0f7353c,
title = "In vivo uptake and metabolism of α-[11C]methyl-L- tryptophan in human brain tumors",
abstract = "Abnormal metabolism of tryptophan has been implicated in modulation of tumor cell proliferation and immunoresistance. α-[11C]Methyl-L- tryptophan (AMT) is a PET tracer to measure cerebral tryptophan metabolism in vivo. In the present study, we have measured tumor tryptophan uptake in 40 patients with primary brain tumors using AMT PET and standard uptake values (SUV). Tryptophan metabolism was further quantified in 23 patients using blood input data. Estimates of the volume of distribution (VD′) and the metabolic rate constant (k′3) were calculated and related to magnetic resonance imaging (MRI) and histology findings. All grade II to IV gliomas and glioneuronal tumors showed increased AMT SUV, including all recurrent/residual tumors. Gadolinium enhancement on MRI was associated with high VD values, suggesting impaired blood-brain barrier, while k′3 values were not related to contrast enhancement. Low-grade astrocytic gliomas showed increased tryptophan metabolism, as measured by k′3. In contrast, oligodendrogliomas showed high VD′ values but lower k′3 as compared with normal cortex. In astrocytic tumors, low grade was associated with high k′3 and lower VD′, while high-grade tumors showed the reverse pattern. The findings show high AMT uptake in primary and residual/recurrent gliomas and glioneuronal tumors. Increased AMT uptake can be due to increased metabolism of tryptophan and/ or high volume of distribution, depending on tumor type and grade. High tryptophan metabolic rates in low-grade tumors may indicate activation of the kynurenine pathway, a mechanism regulating tumor cell growth. AMT PET might be a useful molecular imaging method to guide therapeutic approaches aimed at controlling tumor cell proliferation by acting on tryptophan metabolism.",
keywords = "Blood-brain barrier, Brain tumors, Glioma, Molecular brain imaging, Positron emission tomography, Tryptophan metabolism",
author = "Csaba Juh{\'a}sz and Chugani, {Diane C.} and Otto Muzik and Dafang Wu and Sloan, {Andrew E.} and Geoffrey Barger and Craig Watson and Shah, {Aashit K.} and Sandeep Sood and Ergun, {Eser L.} and Mangner, {Tom J.} and Chakraborty, {Pulak K.} and Kupsky, {William J.} and Chugani, {Harry T.}",
year = "2006",
month = "3",
doi = "10.1038/sj.jcbfm.9600199",
language = "English (US)",
volume = "26",
pages = "345--357",
journal = "Journal of Cerebral Blood Flow and Metabolism",
issn = "0271-678X",
publisher = "Nature Publishing Group",
number = "3",

}

TY - JOUR

T1 - In vivo uptake and metabolism of α-[11C]methyl-L- tryptophan in human brain tumors

AU - Juhász, Csaba

AU - Chugani, Diane C.

AU - Muzik, Otto

AU - Wu, Dafang

AU - Sloan, Andrew E.

AU - Barger, Geoffrey

AU - Watson, Craig

AU - Shah, Aashit K.

AU - Sood, Sandeep

AU - Ergun, Eser L.

AU - Mangner, Tom J.

AU - Chakraborty, Pulak K.

AU - Kupsky, William J.

AU - Chugani, Harry T.

PY - 2006/3

Y1 - 2006/3

N2 - Abnormal metabolism of tryptophan has been implicated in modulation of tumor cell proliferation and immunoresistance. α-[11C]Methyl-L- tryptophan (AMT) is a PET tracer to measure cerebral tryptophan metabolism in vivo. In the present study, we have measured tumor tryptophan uptake in 40 patients with primary brain tumors using AMT PET and standard uptake values (SUV). Tryptophan metabolism was further quantified in 23 patients using blood input data. Estimates of the volume of distribution (VD′) and the metabolic rate constant (k′3) were calculated and related to magnetic resonance imaging (MRI) and histology findings. All grade II to IV gliomas and glioneuronal tumors showed increased AMT SUV, including all recurrent/residual tumors. Gadolinium enhancement on MRI was associated with high VD values, suggesting impaired blood-brain barrier, while k′3 values were not related to contrast enhancement. Low-grade astrocytic gliomas showed increased tryptophan metabolism, as measured by k′3. In contrast, oligodendrogliomas showed high VD′ values but lower k′3 as compared with normal cortex. In astrocytic tumors, low grade was associated with high k′3 and lower VD′, while high-grade tumors showed the reverse pattern. The findings show high AMT uptake in primary and residual/recurrent gliomas and glioneuronal tumors. Increased AMT uptake can be due to increased metabolism of tryptophan and/ or high volume of distribution, depending on tumor type and grade. High tryptophan metabolic rates in low-grade tumors may indicate activation of the kynurenine pathway, a mechanism regulating tumor cell growth. AMT PET might be a useful molecular imaging method to guide therapeutic approaches aimed at controlling tumor cell proliferation by acting on tryptophan metabolism.

AB - Abnormal metabolism of tryptophan has been implicated in modulation of tumor cell proliferation and immunoresistance. α-[11C]Methyl-L- tryptophan (AMT) is a PET tracer to measure cerebral tryptophan metabolism in vivo. In the present study, we have measured tumor tryptophan uptake in 40 patients with primary brain tumors using AMT PET and standard uptake values (SUV). Tryptophan metabolism was further quantified in 23 patients using blood input data. Estimates of the volume of distribution (VD′) and the metabolic rate constant (k′3) were calculated and related to magnetic resonance imaging (MRI) and histology findings. All grade II to IV gliomas and glioneuronal tumors showed increased AMT SUV, including all recurrent/residual tumors. Gadolinium enhancement on MRI was associated with high VD values, suggesting impaired blood-brain barrier, while k′3 values were not related to contrast enhancement. Low-grade astrocytic gliomas showed increased tryptophan metabolism, as measured by k′3. In contrast, oligodendrogliomas showed high VD′ values but lower k′3 as compared with normal cortex. In astrocytic tumors, low grade was associated with high k′3 and lower VD′, while high-grade tumors showed the reverse pattern. The findings show high AMT uptake in primary and residual/recurrent gliomas and glioneuronal tumors. Increased AMT uptake can be due to increased metabolism of tryptophan and/ or high volume of distribution, depending on tumor type and grade. High tryptophan metabolic rates in low-grade tumors may indicate activation of the kynurenine pathway, a mechanism regulating tumor cell growth. AMT PET might be a useful molecular imaging method to guide therapeutic approaches aimed at controlling tumor cell proliferation by acting on tryptophan metabolism.

KW - Blood-brain barrier

KW - Brain tumors

KW - Glioma

KW - Molecular brain imaging

KW - Positron emission tomography

KW - Tryptophan metabolism

UR - http://www.scopus.com/inward/record.url?scp=33644537101&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33644537101&partnerID=8YFLogxK

U2 - 10.1038/sj.jcbfm.9600199

DO - 10.1038/sj.jcbfm.9600199

M3 - Article

VL - 26

SP - 345

EP - 357

JO - Journal of Cerebral Blood Flow and Metabolism

JF - Journal of Cerebral Blood Flow and Metabolism

SN - 0271-678X

IS - 3

ER -